Home Finance & Business Laprophan IPO draws nearly seven times more money than shares on offer

Laprophan IPO draws nearly seven times more money than shares on offer

Laprophan IPO attracts 15.3bn dirhams in investor orders
Laprophan IPO attracts 15.3bn dirhams in investor orders

Moroccan pharmaceutical company Laprophan has attracted strong investor demand for its stock market debut, with investors placing orders worth 15.3bn dirhams — nearly seven times the value of shares on offer. About 44,000 investors took part in the IPO, according to Bachir Tazi, executive director of CFG Bank, which is overseeing the operation. The final results are expected on 25 November.

The IPO is valued at 2.22bn dirhams, making it the biggest listing on the Casablanca Stock Exchange so far this year and the third company to join the market in 2026.

Laprophan’s offering combines newly issued shares with shares sold by existing shareholders. The company plans to use the proceeds to support its expansion, including the planned acquisition of Polymedic, another pharmaceutical manufacturer.

Polymedic recorded nearly 405m dirhams in revenue in 2025. The acquisition is still subject to regulatory approval.

Laprophan operates four production sites in Morocco and Switzerland. Its revenue rose to 1.82bn dirhams in 2025, from 1.638bn dirhams in 2024, an increase of about 11.1%.

The strong demand makes Laprophan’s IPO one of the year’s major events on the Casablanca financial market, with investors seeking nearly seven times more shares than were available.

Final results, including the allocation of shares to investors, are expected to be announced on 25 November.

Exit mobile version